Novel Natural-based Biomolecules Discovery for Tackling Chronic Diseases
Natural-based biomolecules continuously play an important role in novel drug discovery for the treatment of chronic diseases. The development of natural peptide/protein-based, toxin-based, and antibody-based drugs can significantly improve the biomedical efficiency of disease-specific therapy. The f...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04507naaaa2201141uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_68520 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-0365-0387-5 | ||
| 020 | |a 9783036503868 | ||
| 020 | |a 9783036503875 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-0387-5 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a H |2 bicssc | |
| 072 | 7 | |a JFFP |2 bicssc | |
| 100 | 1 | |a Kwok, Hang Fai |4 edt | |
| 700 | 1 | |a Kwok, Hang Fai |4 oth | |
| 245 | 1 | 0 | |a Novel Natural-based Biomolecules Discovery for Tackling Chronic Diseases |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (180 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Natural-based biomolecules continuously play an important role in novel drug discovery for the treatment of chronic diseases. The development of natural peptide/protein-based, toxin-based, and antibody-based drugs can significantly improve the biomedical efficiency of disease-specific therapy. The focus of this Special Issue of Biomolecules will be on the most recent advances related to novel peptides/proteins, antibodies, and toxins as forms of medicinal therapy. Recent advances in the discovery and development of these natural biomolecules for use in targeted therapy and immunotherapy against chronic diseases (e.g., cancer, diabetes, cardiovascular diseases, and rheumatoid arthritis) will be addressed. The discussion on using novel disease-specific proteins/peptides/toxins/antibodies along with currently available FDA-approved drugs as combinatorial treatments will also be encouraged in this context. Finally, an overview of some of the selected promising natural biomolecules that are potentially able to address the forthcoming challenges in this field will be included. Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Humanities |2 bicssc | |
| 650 | 7 | |a Social interaction |2 bicssc | |
| 653 | |a DAPK1 | ||
| 653 | |a SUMO | ||
| 653 | |a SENP | ||
| 653 | |a protein degradation | ||
| 653 | |a post-translational modification | ||
| 653 | |a amphibian Bowman-Birk inhibitor | ||
| 653 | |a Tat peptide | ||
| 653 | |a molecular cloning | ||
| 653 | |a antifungal | ||
| 653 | |a drug design | ||
| 653 | |a protease inhibitor | ||
| 653 | |a natural-based compound | ||
| 653 | |a anticancer therapy | ||
| 653 | |a lung cancer | ||
| 653 | |a survivin | ||
| 653 | |a apoptosis | ||
| 653 | |a STAT3 | ||
| 653 | |a colorectal cancer | ||
| 653 | |a orientin | ||
| 653 | |a cell cycle arrest | ||
| 653 | |a Bcl-2 family proteins | ||
| 653 | |a Astragalus membranaceus | ||
| 653 | |a insulin | ||
| 653 | |a PI3K | ||
| 653 | |a AKT | ||
| 653 | |a PPARγ | ||
| 653 | |a PDX-1 | ||
| 653 | |a Petasites japonicus | ||
| 653 | |a Asteraceae | ||
| 653 | |a lignan | ||
| 653 | |a anti-inflammation | ||
| 653 | |a NO | ||
| 653 | |a PGE2 | ||
| 653 | |a iNOS | ||
| 653 | |a COX-2 | ||
| 653 | |a molecular docking | ||
| 653 | |a peptides | ||
| 653 | |a kynurenines | ||
| 653 | |a binding affinity | ||
| 653 | |a μ-opioid receptor | ||
| 653 | |a pharmacophore | ||
| 653 | |a G-protein activation | ||
| 653 | |a fucoidan | ||
| 653 | |a PLGA | ||
| 653 | |a docetaxel | ||
| 653 | |a drug delivery system | ||
| 653 | |a anticancer therapy/cancer treatment | ||
| 653 | |a hIAPP | ||
| 653 | |a amyloidogenesis | ||
| 653 | |a insulin granules | ||
| 653 | |a endoplasmic reticulum | ||
| 653 | |a anionic lipids | ||
| 653 | |a F23R variant | ||
| 653 | |a β-sheet transitions | ||
| 653 | |a β-cell cytotoxicity | ||
| 653 | |a unfolded protein response | ||
| 653 | |a pomegranate | ||
| 653 | |a punicalagin | ||
| 653 | |a tannins | ||
| 653 | |a gingiva | ||
| 653 | |a fibroblasts | ||
| 653 | |a antioxidant | ||
| 653 | |a wound healing | ||
| 653 | |a branched-chain fatty acids | ||
| 653 | |a Conidiobolus heterosporus | ||
| 653 | |a peroxisome proliferator-activated receptor α | ||
| 653 | |a lipid metabolism | ||
| 653 | |a fatty acid oxidation | ||
| 653 | |a hepatocyte | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3541 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68520 |7 0 |z DOAB: description of the publication |